Idiopathic Pulmonary Fibrosis News and Research RSS Feed - Idiopathic Pulmonary Fibrosis News and Research

Pulmonary fibrosi is a condition in which tissue deep in your lungs becomes thick and stiff, or scarred, over time. The development of the scarred tissue is called fibrosis. As the lung tissue becomes thicker, your lungs lose their ability to move oxygen into your bloodstream. As a result, your brain and other organs don't get the oxygen they need.

In some cases, doctors can find out what's causing the fibrosis. But in most cases, they can't find a cause. They call these cases idiopathic pulmonary fibrosis (IPF). IPF is a serious condition. About 200,000 Americans have it. About 50,000 new cases are diagnosed each year. IPF mostly affects people who are 50 to 75 years of age. IPF varies from person to person. In some people, the lung tissue quickly becomes thick and stiff. In others, the process is much slower. In some people, the condition stays the same for years. IPF has no cure yet. Many people live only about 3 to 5 years after diagnosis. The most common cause of death related to IPF is respiratory failure.
Study shows pro-inflammatory cytokine TNF-α can speed recovery in mouse with  pulmonary fibrosis

Study shows pro-inflammatory cytokine TNF-α can speed recovery in mouse with pulmonary fibrosis

Inflammation has long been considered an integral part of the biological process that leads to deadly scarring in idiopathic pulmonary fibrosis. New research at National Jewish Health, however, suggests that a little inflammation may also be crucial to the healing and repair processes in the lungs. [More]
Genoa Pharmaceuticals, McMaster University report additional benefits of GP-101 for IPF patients

Genoa Pharmaceuticals, McMaster University report additional benefits of GP-101 for IPF patients

Genoa Pharmaceuticals, the leader in inhaled medicines for pulmonary fibrosis, and collaborators Drs. Martin Kolb and Kjetil Ask at McMaster University announced today additional measured advantages of inhaled GP-101 (aerosol pirfenidone) in the treatment of idiopathic pulmonary fibrosis (IPF). [More]
Genkyotex’s GKT137831 reverses lung fibrosis in new model of idiopathic pulmonary fibrosis

Genkyotex’s GKT137831 reverses lung fibrosis in new model of idiopathic pulmonary fibrosis

Genkyotex, the leading developer of selective NOX enzyme inhibitors, announced today the publication of data showing that GKT137831, a first in class NOX1 and 4 inhibitor, was able to reverse lung fibrosis associated with aging in a new model of idiopathic pulmonary fibrosis. [More]
Research reveals 2 key mechanisms of oxidative stress regulation

Research reveals 2 key mechanisms of oxidative stress regulation

Regulation of oxidative stress is critical to cell survival. New preclinical research from Roswell Park Cancer Institute (RPCI) has revealed two key mechanisms by which oxidative stress is regulated in normal and cancerous cells. [More]
Idiopathic pulmonary fibrosis could soon be diagnosed without the need for surgical lung biopsy

Idiopathic pulmonary fibrosis could soon be diagnosed without the need for surgical lung biopsy

People who have suspected idiopathic pulmonary fibrosis without typical patterns on high resolution computed tomography scans could in future be spared the substantial risks of lung biopsy and be given a confident diagnosis of IPF based on clinical and radiological findings alone, according to new research published in The Lancet Respiratory Medicine. [More]
Cedars-Sinai research team receives grant to develop treatment for idiopathic pulmonary fibrosis

Cedars-Sinai research team receives grant to develop treatment for idiopathic pulmonary fibrosis

​A Cedars-Sinai research team led by Paul W. Noble, MD, chair of the Department of Medicine and director of the Women's Guild Lung Institute, has been awarded $628,816 by California's stem cell agency to develop a treatment for idiopathic pulmonary fibrosis, a deadly disease that destroys the lungs and damages other vital organs. [More]
Boehringer Ingelheim, DCRI partner to uncover insights into idiopathic pulmonary fibrosis

Boehringer Ingelheim, DCRI partner to uncover insights into idiopathic pulmonary fibrosis

Boehringer Ingelheim Pharmaceuticals, Inc. and Duke Clinical Research Institute have formed a unique collaborative relationship to uncover insights into idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. [More]
Pulmonary Fibrosis Foundation selects UofL for newly established Care Center Network

Pulmonary Fibrosis Foundation selects UofL for newly established Care Center Network

The University of Louisville is one of nine pilot sites selected by the Pulmonary Fibrosis Foundation for its newly established Care Center Network and the PFF Patient Registry program. Rafael Perez, M.D., director of the UofL Interstitial Lung Disease program in the Division of Pulmonary, Critical Care & Sleep Disorders Medicine, will lead the UofL site. [More]
Idiopathic pulmonary fibrosis (IPF) and herpesvirus saimiri: an interview with Elazar Rabbani, Chief Executive Officer of Enzo

Idiopathic pulmonary fibrosis (IPF) and herpesvirus saimiri: an interview with Elazar Rabbani, Chief Executive Officer of Enzo

Pulmonary fibrosis is a condition where fibrotic or scarred tissue progressively develops in the lungs. In some cases the particular cause is known but in others it remains unknown and is given the term “idiopathic”. [More]
FibroGen starts patient enrollment in FG-3019 Phase 2 study for idiopathic pulmonary fibrosis treatment

FibroGen starts patient enrollment in FG-3019 Phase 2 study for idiopathic pulmonary fibrosis treatment

FibroGen, Inc., announced today that patient enrollment has started in a new Phase 2 clinical study of FG-3019 in patients who suffer from idiopathic pulmonary fibrosis. [More]
ATS Foundation, American Lung Association to co-fund $80,000 grant to support HPS research

ATS Foundation, American Lung Association to co-fund $80,000 grant to support HPS research

The American Thoracic Society Foundation and the American Lung Association announced today that they are co-funding an $80,000 grant that will support important research into the mechanisms underlying Hermansky-Pudlak syndrome, a rare inherited disease which affects a number of organs including the lungs. [More]
UCD Conway Institute researchers identify potential biomarker of idiopathic pulmonary fibrosis

UCD Conway Institute researchers identify potential biomarker of idiopathic pulmonary fibrosis

Researchers in UCD Conway Institute have identified a potential biomarker of rapidly progressive pulmonary fibrosis and pinpointed a defective molecular function as a potential therapeutic target. [More]
6MWT wording change could enhance serial utility

6MWT wording change could enhance serial utility

Researchers have found that the distance patients cover during the 6-minute walk test depends on the instructions they are given, indicating that changing the current protocol may enhance the accuracy and reproducibility of the test. [More]
Scientists transform human stem cells into functional lung and airway cells

Scientists transform human stem cells into functional lung and airway cells

For the first time, scientists have succeeded in transforming human stem cells into functional lung and airway cells. The advance, reported by Columbia University Medical Center researchers, has significant potential for modeling lung disease, screening drugs, studying human lung development, and, ultimately, generating lung tissue for transplantation. [More]
FibroGen presents China-based Phase 2 study data of roxadustat for treatment of CKD patients

FibroGen presents China-based Phase 2 study data of roxadustat for treatment of CKD patients

FibroGen, Inc. (FibroGen), today announced that data from a China-based Phase 2 study of roxadustat (FG-4592), a first-in-class oral compound in late stage development for the treatment of anemia associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD), were presented in an oral session at the 2013 American Society of Nephrology (ASN) Kidney Week in Atlanta, Georgia. [More]
Findings demonstrate potential new therapeutic approach to treat fibrotic diseases

Findings demonstrate potential new therapeutic approach to treat fibrotic diseases

A team of scientists that includes Saint Louis University researchers has identified a new way to intervene in the molecular and cellular cascade that causes fibrosis - a condition where the body's natural process of forming scars for wound healing goes into overdrive and causes diseases. [More]
Genkyotex announces initiation of GKT137831 Phase II study in patients with diabetic nephropathy

Genkyotex announces initiation of GKT137831 Phase II study in patients with diabetic nephropathy

Genkyotex, the leading developer of selective NOX enzyme inhibitors, announced today the initiation of a multinational Phase II clinical study of GKT137831 in patients with diabetic nephropathy. [More]
Researchers discover link between NOX4 enzyme and osteoporosis

Researchers discover link between NOX4 enzyme and osteoporosis

Genkyotex, the leading developer of NOX enzyme inhibitors, announced today that a group of collaborators have discovered a link between the enzyme NOX4 and development of osteoporosis. [More]
Promedior starts Phase 2 clinical trial to evaluate PRM-151 in patients with myelofibrosis

Promedior starts Phase 2 clinical trial to evaluate PRM-151 in patients with myelofibrosis

Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, announced today that it has initiated a Phase 2 clinical trial to evaluate PRM-151, its lead product candidate, in patients with myelofibrosis. [More]
IPF World Week underlines the need for integrated approach towards idiopathic pulmonary fibrosis

IPF World Week underlines the need for integrated approach towards idiopathic pulmonary fibrosis

This year's IPF World Week (September 21-29) sees healthcare professionals, patient advocacy groups, people living with idiopathic pulmonary fibrosis (IPF), who have an estimated median survival time of two to five years, and their families calling for an integrated approach to further strengthen the national and international network of people working to support patients with this fatal orphan lung disease. [More]
Advertisement